期刊名称：MOLECULAR THERAPY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Molecular Therapy
|
Molecular Therapy is the monthly publication of the American Society of Gene Therapy (ASGT). The journal publishes original scientific papers in the areas of gene transfer, gene regulation, gene discovery, cell therapy, experimental models, correction of genetic and acquired diseases, and clinical trials. Manuscripts describing new methodological advances of interest to a large number of Molecular Therapy readers will also be considered for publication. In addition, Molecular Therapy publishes timely reviews, commentaries, and scientific correspondence. Although Molecular Therapy is the official journal of ASGT, it is international in scope and publication. The major criteria for acceptance and publication of a manuscript are originality, high quality, scientific rigor, and interest to a wide audience of readers. |
|
Instructions to Authors
EDITORIAL POLICIES
Material published in Molecular Therapy consists of opinions and conclusions based on the scientific findings of the authors. Although the Editors and Publisher of Molecular Therapy work hard to ensure the accuracy of all published matter, they cannot accept responsibility or liability, collectively or individually, for any erroneous, misleading, or unintentionally damaging statements that may appear in the journal despite their efforts. Manuscripts submitted for publication in Molecular Therapy may not be under consideration for publication elsewhere, and submission for publication must have been approved by all of the authors and by the institution where the work was carried out. Furthermore, manuscript content cannot have been previously published in any other format (including symposia volumes or any other types of publications). Specific questions about what constitutes prior publication should be addressed to the Editorial Office. Manuscripts that do not meet the general criteria or standards for publication in Molecular Therapy will be immediately returned to the authors without detailed review.
Submission of Manuscripts. There are no submission fees, but there is a charge of $50 per page for articles appearing in Molecular Therapy. Each manuscript should be accompanied by a letter outlining the basic findings of the paper and their significance. The cover letter should also suggest up to five possible reviewers. Authors are required to transmit the text and art of the manuscript via the website http://mthe.edmgr.com. Instructions for uploading files are available on the site. If the authors are unable to submit online, the manuscript may be sent in one of the following forms, along with a specific note of explanation as to why it is not being transmitted via the website. Note that revised versions of papers that were submitted before November 26, 2002 should be sent by e-mail, not uploaded to the website.
Postal Mail: Manuscripts on Floppy disk, Zip-disk, or CD-ROM should be sent to:
Molecular Therapy
Editorial Office
525 B Street, Suite 1900
San Diego, CA 92101-4495
USA
E-mail (moltherapy@elsevier.com): Submission as an e-mail attachment is acceptable provided that all files are included in a single archive the size of which does not exceed 2 megabytes.
FTP (ftp://ftp.harcourtbrace.com/pub/academic_press/saved/moltherapy): An e-mail should be sent notifying the Editorial Office of any FTP submissions (along with an explanation of why the manuscript files were not uploaded via the website).
Presubmission Inquiries. An increasing number of journals are accepting "presubmission inquiries," that is, author queries regarding the suitability of a manuscript before submission. Molecular Therapy editors are willing to consider presubmission inquiries. However, authors must realize that a positive response to a presubmission inquiry merely suggests an interest in reviewing the paper. A positive response to a presubmission inquiry in no way represents an offer to publish the manuscript, nor does it take the place of the usual rigorous peer-review process. Presubmission inquiries should be directed to the Editor at (619) 699-6750 or moltherapy@elsevier.com (e-mail).
Copyright. Authors submitting a manuscript do so on the understanding that if the manuscript is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the American Society of Gene Therapy. The Copyright Transfer Agreement should be signed by the appropriate person and does not take place unless the manuscript is accepted for publication. Authors are responsible for obtaining permissions to reprint previously published figures, tables, and other material. Letters of permission should accompany the final submission.
Molecular Therapy publishes three types of primary articles:
Articles. These are basic and/or preclinical studies applying gene therapy or other molecular medicine interventions to specific disease models or biological problems, or studies aimed at establishing proof-of-principle for novel therapeutic approaches. Organization should be: Abstract, Introduction, Results, Discussion, Materials and Methods, Acknowledgments, and References. There is a limit of 8 display items (figures plus tables) and 50 references. Manuscripts should be no more than eight published pages. Accepted papers that are over eight pages may be returned to the authors for additional editing.
Methods. These are studies defining new methodological tools or significant improvements over established methods.
Trials. These articles report the results of human clinical trials of gene therapy and other molecular medicine approaches to disease.
In addition, Molecular Therapy publishes the following:
Letters to the editor. Short, succinct statements and/or opinions responding to articles published in Molecular Therapy or commenting on events that have an impact on the gene therapy community as a whole. These letters do not contain primary data.
Commentaries. These are short descriptions and analyses of important articles published in Molecular Therapy or elsewhere, events in gene therapy, or social, ethical, or political issues of interest to Molecular Therapy readers. They are the opinion of the author, not the editorial board or the ASGT. These are generally solicited by the editor, although unsolicited submissions will be considered for possible publication.
Reviews. These are succinct reviews written by experts in the subject area of the review, which not only outline the "state of the art," but also try to project future directions. Again, these are largely solicited pieces, although review suggestions will be evaluated for interest to the readership.
Histories. These are solicited papers that attempt to capture specific events and personalities in the history of gene therapy, and put them in the context of their contribution to current understandings. These are only solicited, although suggestions for possible topics/people will be considered.
PREPARATION OF MANUSCRIPT
Manuscripts submitted as hard copies should be double-spaced throughout on one side of 8.5 3 11-inch or A4 white paper. Pages should be numbered consecutively and organized as follows:
The Title Page (p. 1) should contain the article title (20 words or less), authors' names and complete affiliations, and the address for manuscript correspondence (including e-mail address and telephone and fax numbers). Affiliations should be footnoted using superscripted Arabic numerals (for example, 1, 2, 3, etc.). Present addresses, equal co-authors, and the corresponding author should be footnoted using the following symbols, in order: *,  ,  , ?,  , #.
The Abstract (p. 2) must be a single paragraph that summarizes the main findings of the paper in less than 200 words. After the abstract a list of up to 10 key words that will be useful for indexing or searching should be included (please use MeSH terminology, see http://www.nlm.nih.gov/mesh/meshhome.html). The Abstract should not be referenced. Reviews, Commentaries, and Letters to the Editor do not require an abstract.
The Introduction should be as concise as possible, without subheadings.
Results and Discussion may be combined and may be organized into subheadings.
Materials and Methods should be sufficiently detailed to enable the experiments to be reproduced. Names of manufacturers and their locations should be provided in parentheses.
Acknowledgments should be brief and should precede the references. Individuals should be referred to by their full first name and surname, with their affiliation in parentheses. Titles (Dr., Professor, Mrs., etc.) are not permitted.
References should be cited in the text in numerical order (1, 2, 3, ..., n). Reference numbers should be enclosed in brackets (for example, "Jones and colleagues [3] found that...") and should precede figure call-outs. Arrange the reference list in numerical order as the references occur in the text, followed by those in the figure legends and tables. For references with more than six authors, please list only the first author followed by et al. (preceded by a comma). Only articles that have been published or are in press should be included in the references. Unpublished results or personal communications should be cited as such in the text. Personal communications must include the date and the affiliation of the person communicating the material. Submitted manuscripts should not be cited in the reference list, but instead inserted in the text as follows: (J. Smith and R. Davis, manuscript submitted). The names of journals should be abbreviated according to the most recent edition of the List of Journals Indexed in Index Medicus (http://www.nlm.nih.gov/tsd/serials/lji.html).
- 1. Hagag, N., and Viola, M. V. (1993). Chromosome Microdissection and Cloning: A Practical Guide, Academic Press, San Diego.
- 2. Reichert, U., Michel, S., and Schmidt, R. (1993). The cornified envelope: a key structure of terminally differentiating keratinocytes. In Molecular Biology of the Skin: The Keratinocyte (M. Darmon and M. Blumenberg, Eds.), pp. 107-150. Academic Press, San Diego.
- 3. Curran, M. A., Kaiser, S. M., Achacoso, P. L., and Nolan, G. P. (2000). Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol. Ther. 1: 31-38.
The manuscript length can be estimated by the total number of characters (spaces included), not the number of typed pages. The average number of characters per published page is approximately 7000. Count each table or figure as 2450 characters and add to the character count of your manuscript text. In other words, a regular submission should have no more than 56,000 characters (that is, eight published pages).
Nomenclature, Abbreviations, and Symbols. Authors must use approved nomenclature for all genes. Please obtain approved gene symbols before submission. Copies of correspondence documenting the approval of any new gene symbols should accompany all submissions. All unapproved symbols must be replaced with approved symbols (throughout the text and figures). For the human gene database and submission guidelines, see the HUGO gene nomenclature site (http://www.gene.ucl.ac.uk/nomenclature/). For the mouse gene database and submission guidelines, see the Mouse Genome Informatics site (http://www.informatics.jax.org/). For databases for other organisms, see http://www.gene.ucl.ac.uk/ nomenclature/databases.shtml. In mouse, mutant strains and transgenic alleles also require approved symbols, see http://www.informatics.jax.org/. Use of unapproved gene symbols will likely delay publication.
Human and mouse protein symbols should be denoted in all capital letters (for example, FGF8). Use of "h" and "m" prefixes to distinguish between human and mouse proteins is not permitted. Instead, "mouse" or "human" should be inserted before the relevant protein symbol in cases where it is necessary to distinguish between human and mouse proteins. (This protocol extends to proteins of all other organisms.)
Authors must use SI units and follow the guidelines for abbreviations and symbols of the IUPAC-IUBMB Joint Commission on Biochemical Nomenclature (http://www.chem.qmw.ac.uk/iupac/jcbn/).
Figures. Figures should be high-resolution TIFF or EPS files. (Please review the Electronic Artwork Submission link on the Author Gateway, accessible through the journal homepage. PowerPoint figures are unsuitable for publication.) Each figure must be submitted on a separate sheet-not embedded in the text. Indicate the top and the authors on the back of each figure. Lettering on drawings should be of professional quality or generated as high-resolution computer graphics and must be large enough to withstand appropriate reduction for publication.
Figures should be numbered (1, 2, 3, etc.) in the order in which they are referred to in the text. Figure panels are denoted with uppercase Arabic letters (A, B, C, etc.) and are cited in the text as follows: (Fig. 1A) (Figs. 1A and 1B) (Figs. 1 and 2B). (Figure subpanels, for example B1, B (i), Ba, etc., are not permitted.) In figure legends, panel designations are always enclosed in parentheses: (A) (B, C). Figure legends should begin with a brief title.
Color Figures. One color plate will be published free of charge in each article, provided color is deemed scientifically necessary by the reviewers and the Editorial Board. Additional color figures will be charged to the author, unless color is required by the Editorial Board. Beginning in 2003, payment will be required upon acceptance, before publication. Exemption from payment of color page charges can be allowed under conditions of economic hardship and are made at the Editor's discretion. The cost for each additional published page of color figures is US$950.
Tables. Tables should be numbered consecutively with Arabic numerals (1, 2, 3, etc.) in the order in which they are referred to in the text. Type each table (double-spaced) on a separate page (not embedded in the text) with a short descriptive title typed directly above and with essential footnotes below. Table footnotes should be denoted using superscripted lowercase Arabic letters (a, b, c, etc.), not symbols. Authors must submit tables in Microsoft Word format.
Proofs. Proofs will be sent to the corresponding author. Upon acceptance, the manuscript will be edited according to the style of the journal, and proofs should be reviewed carefully. Please be sure to answer all author queries. To avoid delay in publication, only necessary changes should be made, and proofs should be returned within 24 hours. Failure to do so will result in publication delays. Authors will be charged for alterations that exceed 10% of the total cost of composition.
Sharing Information and Materials. It is expected that all new biological or other reagents described in papers published in Molecular Therapy will be made available freely to all qualified members of the scientific community upon written request. If delays in strain or vector distribution are anticipated, or if these are available from sources other than the author(s), this must be indicated and, if the Editors think it necessary, explained.
Submission of Data to Databases. The editorial policy of Molecular Therapy is to require the use of databases. Deposit of data in the appropriate database(s) is a condition of publication. New nucleotide data must be submitted and deposited in the DDBJ/EMBL/GenBank databases and an accession number obtained before the paper can be accepted for publication. Submission to any one of the three collaborating databanks is sufficient to ensure data entry in all. The accession number should be included in the manuscript. If requested, the database will withhold release of data until publication. The most convenient method for submitting sequence data is by the World-Wide Web: DDBJ via SAKURA, http://sakura.ddbj.nig.ac.jp/; EMBL via WEBIN, http://www.ebi.ac.uk/embl/Submission/webin.html; GenBank via BankIt, http://www.ncbi.nlm.nih.gov/BankIt/; stand-alone submission tool Sequin, http://www.ncbi.nlm.nih.gov/Sequin/; Mouse Genome Informatics, http://www.informatics.jax.org/mgihome/. For special types of submissions (for example, genomes, bulk submissions, and so on) additional submission protocols are available from the above sites.
Database contact information:
DDBJ: Center for Information Biology and DNA Data Bank of Japan, National Institute of Genetics, 1111 Yata, Mishima, Shizuoka 411-8540, Japan; telephone: +81 55981 6853; fax: +81 55981 6849; e-mail: ddbj@ddbj.nig.ac.jp; web URL: http://www.ddbj.nig.ac.jp/
EMBL: EMBL Nucleotide Sequence Submissions, European Bioinformatics Institute. Wellcome Trust Genome Campus. Hinxton, Cambridge CB10 1SD UK; telephone: +44 1223 494499; fax: +44 1223 494472; e-mail: datasubs@ebi.ac.uk; web URL: http://www.ebi.ac.uk
GenBank: National Center for Biotechnology Information, National Library of Medicine, Bldg. 38A, Rm 8N-802 Bethesda, MD 20894, USA; telephone: +1 301 496 2475; fax: +1 301 480 9241; e-mail: info@ncbi.nlm.nih.gov; web URL: http://www.ncbi.nlm.nih.gov
Editorial Board
-
- Editor-in-Chief:
- I.M. Verma, The Salk Institute, California, USA
- Editor:
- R.M. Frederickson
- Associate Editors:
- M.K. Brenner
J.C. Glorioso
L. Huang
D.B. Kohn
E.G. Nabel
I.L. Weissman
J.M. Wilson
- Editorial Board
- E. Aguilar-Cordova
J.-P. Behr
R.M. Blaese
H.M. Blau
D. Bodine
X.O. Breakefield
H. Bujard
P. Burd
J. Chamberlain
S.H. Cheng
C. Coutelle
R.G. Crystal
D.T. Curiel
O. Danos
B.L. Davidson
J.E. Dick
C.E. Dunbar
V. Dzau
P.L. Felgner
T. Friedmann
F.H. Gage
M. Grompe
S.D. Hauschka
K. High
Y. Kaneda
G. Karpati
M.A. Kay
S. Kingsman
J.M. Leiden
K. Leong
M.A. Liu
P. Lowenstein
D. Miller
R.C. Mulligan
N. Muzyczka
G.J. Nabel
L. Naldini
A.W. Nienhuis
G.P. Nolan
D. Pardoll
M. Perricaudet
J.J. Rossi
D. Russell
S.J. Russell
M. Sadelain
C.R. Safinya
I. Saito
R.J. Samulski
A.E. Smith
G. Stamatoyannopoulos
F. Szoka, Jr.
D. Trono
D. Valerio
M.D. Weitzman
D.A. Williams
J.A. Wolff
S.L.C. Woo
|
